Z S Guo

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. pmc De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model
    Z Sheng Guo
    Thoracic Oncology Section and Tumor Immunology Section, Surgery Branch, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Cancer Res 66:1105-13. 2006
  2. pmc Oncolytic viruses as therapeutic cancer vaccines
    David L Bartlett
    University of Pittsburgh Cancer Institute and Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Mol Cancer 12:103. 2013
  3. pmc Homeobox gene Rhox5 is regulated by epigenetic mechanisms in cancer and stem cells and promotes cancer growth
    Qiang Li
    The University of Pittsburgh Cancer Institute, University of Pittsburgh, Pennsylvania 15213, USA
    Mol Cancer 10:63. 2011
  4. pmc The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host
    Z S Guo
    The University of Pittsburgh Cancer Institute and Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Gene Ther 17:1465-75. 2010
  5. doi request reprint Gene transfer: the challenge of regulated gene expression
    Z Sheng Guo
    Division of Surgical Oncology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Trends Mol Med 14:410-8. 2008
  6. pmc Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses
    Z Sheng Guo
    University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Biochim Biophys Acta 1785:217-31. 2008
  7. pmc Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer
    M Sathaiah
    Department of Surgery, University of Pittsburgh School of Medicine, and the University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Cancer Gene Ther 19:192-201. 2012
  8. pmc TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer
    M F Ziauddin
    Department of Surgery, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Gene Ther 17:550-9. 2010
  9. pmc Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene
    S Chalikonda
    Department of Surgery, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Gene Ther 15:115-25. 2008
  10. doi request reprint Inhibitors of C5 complement enhance vaccinia virus oncolysis
    D Magge
    Department of Surgery, University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA 15213, USA
    Cancer Gene Ther 20:342-50. 2013

Collaborators

Detail Information

Publications20

  1. pmc De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model
    Z Sheng Guo
    Thoracic Oncology Section and Tumor Immunology Section, Surgery Branch, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Cancer Res 66:1105-13. 2006
    ..These data show a novel strategy of combined chemoimmunotherapy of cancer targeting a CTA induced de novo in a broad range of tumor histologies, and support further evaluation of chromatin-remodeling agents for human cancer therapy...
  2. pmc Oncolytic viruses as therapeutic cancer vaccines
    David L Bartlett
    University of Pittsburgh Cancer Institute and Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Mol Cancer 12:103. 2013
    ..Combination with cyclophosphamide further induces ICD, depletes Treg, and thus potentiates antitumor immunity. In summary, OVs properly armed or in rational combinations are potent therapeutic cancer vaccines. ..
  3. pmc Homeobox gene Rhox5 is regulated by epigenetic mechanisms in cancer and stem cells and promotes cancer growth
    Qiang Li
    The University of Pittsburgh Cancer Institute, University of Pittsburgh, Pennsylvania 15213, USA
    Mol Cancer 10:63. 2011
    ..Here we study the epigenetic regulation and potential functions of Rhox5 gene...
  4. pmc The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host
    Z S Guo
    The University of Pittsburgh Cancer Institute and Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Gene Ther 17:1465-75. 2010
    ..These results showed the feasibility of treating pre-vaccinated patients with peritoneal carcinomatosis using an oncolytic poxvirus and a combined immune intervention strategy...
  5. doi request reprint Gene transfer: the challenge of regulated gene expression
    Z Sheng Guo
    Division of Surgical Oncology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Trends Mol Med 14:410-8. 2008
    ..We highlight the potential applications in gene transfer, gene therapy for cancer and genetic disease and the future challenges for clinical applications...
  6. pmc Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses
    Z Sheng Guo
    University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Biochim Biophys Acta 1785:217-31. 2008
    ..Finally, we will highlight some avenues deserving further study in order to achieve the ultimate goals of utilizing various OVs for effective cancer treatment...
  7. pmc Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer
    M Sathaiah
    Department of Surgery, University of Pittsburgh School of Medicine, and the University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Cancer Gene Ther 19:192-201. 2012
    ..FasR induction provides one mechanism for tumor-selective replication of oncolytic poxviruses in FasR- cancers with enhanced safety. The overall result is both a safer and more effective oncolytic virus for FasR- cancer...
  8. pmc TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer
    M F Ziauddin
    Department of Surgery, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Gene Ther 17:550-9. 2010
    ..This combination strategy may provide a new avenue to treating peritoneal carcinomatosis and other types of metastases of colorectal cancer...
  9. pmc Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene
    S Chalikonda
    Department of Surgery, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Gene Ther 15:115-25. 2008
    ..Given the biological safety, tumor selectivity and oncolytic potency of this armed oncolytic virus, this dual therapy merits further investigation as a promising new treatment for metastatic ovarian cancer...
  10. doi request reprint Inhibitors of C5 complement enhance vaccinia virus oncolysis
    D Magge
    Department of Surgery, University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA 15213, USA
    Cancer Gene Ther 20:342-50. 2013
    ..This study suggests that complement inhibition may reduce vaccinia viral neutralization and may be critical to future in vivo work...
  11. ncbi request reprint Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1
    T S Weiser
    Thoracic Oncology Section, Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892-1502, USA
    J Immunother 24:151-61. 2001
    ..Although the mechanisms have not been fully defined, sequential DAC-DP treatment may be a novel strategy to augment antitumor immunity in cancer patients...
  12. ncbi request reprint A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus
    S Yang
    University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Gene Ther 14:638-47. 2007
    ..This study illustrates the complexity of creating a tumor-selective oncolytic virus by deleting multiple viral genes involved in multiple cellular pathways...
  13. ncbi request reprint Vaccinia as a vector for gene delivery
    Z Sheng Guo
    University of Pittsburgh, Division of Surgical Oncology, 5150 Center Avenue, Suite 459, Pittsburgh, PA 15232, USA
    Expert Opin Biol Ther 4:901-17. 2004
    ..Other potential strategies for improving this vector for gene delivery will also be discussed in this review...
  14. ncbi request reprint Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228
    Xiaodan Yu
    Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Natl Cancer Inst 94:504-13. 2002
    ..This study evaluated the mechanisms by which FK228 mediates apoptosis in non-small-cell lung cancer (NSCLC) cells...
  15. ncbi request reprint The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2
    Z Sheng Guo
    Division of Surgical Oncology, University of Pittsburgh Cancer Institute, PA 15232, USA
    Cancer Res 65:9991-8. 2005
    ..Given its enhanced tumor selectivity, improved safety profile, and substantial oncolytic effects following systemic delivery in murine models, it should also serve as a useful vector for tumor-directed gene therapy...
  16. ncbi request reprint Intravenous and isolated limb perfusion delivery of wild type and a tumor-selective replicating mutant vaccinia virus in nonhuman primates
    Arpana M Naik
    Center for Cancer Research, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Hum Gene Ther 17:31-45. 2006
    ..These results suggest that vvDD appears to be safe in primates, and thus vvDD should be further investigated for clinical trial in human cancer patients...
  17. doi request reprint Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms
    Qiang Li
    University of Pittsburgh Cancer Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Mol Pharmacol 76:1072-81. 2009
    ....
  18. ncbi request reprint High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists
    Petar J Popovic
    Division of Surgical Oncology, Department of Surgery and Molecular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15232, USA
    J Immunol 177:8701-7. 2006
    ..Our observations suggest that HMGB1 may play a critical role in regulating the immune response during chronic inflammation and tissue damage through modulation of PDC function...
  19. ncbi request reprint An optimal therapeutic expression level is crucial for suicide gene therapy for hepatic metastatic cancer in mice
    Yasuhiro Terazaki
    Department of Surgery, Kurume University School of Medicine, Japan
    Hepatology 37:155-63. 2003
    ..The present results, which contradict those of previous studies, alert researchers about possible problems with ongoing and future clinical trials that lack this concept...
  20. pmc Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy
    Wenxian Hu
    Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Biol Ther 6:1773-9. 2007
    ..Taken together, these results suggest that redirecting adaptive immunity against foreign antigens is a potential approach for anticancer therapy and that pre-existing immunity could enhance virotherapy against cancers...